Skip to content

2020 Abstracts

View all abstracts in full here

Poster NumberPoster Title
P1Endothelial inducible T cell co-stimulator ligand (ICOSL) regulates adhesion molecule expression on liver endothelium: implications for senescence-mediated immune surveillance
P2L1 retrotransposable elements accumulates in Hepatitis C virus (HCV) infected liver cancer cells
P3Direct acting antivirals reduce development of hepatocellular carcinoma in cirrhotic hepatitis C patients
P4Baseline liver function and outcomes in the phase 3 REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR): Assessment of overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and safety
P5Evaluation of ALPPS and PVE in management of HCC
P6The role of soluble checkpoint receptor and intestinal permeability in Hepatocellular Carcinoma (HCC)
P7A neutrophil metabolic switch in patients with hepatocellular carcinoma
P8Cost-effectiveness of lenvatinib in the treatment of hepatocellular carcinoma in the United Kingdom
P9A specialist HCC clinic improves time to treatment: The Oxford experience.
P10Healthcare resource use among patients with advanced hepatocellular carcinoma (aHCC) in the UK
P11A single liver transplant centre experience of an imaging based surveillance programme for HCC recurrence following liver transplantation
P12The HUNTER: Hepatocellular Carcinoma Expediter Network Registry
P13Experience of HCC patient on an ongoing study with ADP-A2AFP SPEAR T-cells

Call us on: 01543 442154

Email: [email protected]

HCC-UK

C/O Executive Business Support

City Wharf, Davidson Road

Lichfield, Staffordshire

WS14 9DZ